10th International Meeting on Replicating Oncolytic Virus Therapeutics

10th International Meeting on Replicating Oncolytic Virus Therapeutics

 

Several members of the Vyriad team, Drs. Stephen Russell, Alice Bexon, Kah-Whye Peng, Rosa Maria (Memy) Diaz, Shruthi Naik, attended and participated in the 10th International Meeting on Replicating Oncolytic Virus Therapeutics, October 1-4, 2016, in Vancouver.

  • Vyriad was a Gold level sponsor of the meeting and was recognized for supporting a highly successful and informative debate between Drs. Rob Coffin (Replimmune) and Kerry Fisher (Psioxus) entitled “This house believes that intravenous administration is the most realistic approach by which oncolytic virus therapy will enter routine clinical practice”. See twitter feed by Imanis Life Sciences.

 

  • Kah-Whye Peng, PhD, CTO of Vyriad gave a Plenary presentation entitled “Vesicular stomatitis virus (VSV) as an oncolytic agent”

 

  • Stephen J. Russell, MD, PhD, CEO & President of Vyriad gave a Plenary presentation entitled “Measles as a versatile oncolytic agent”

 

At the closing banquet, Dr. Russell was announced as the 2016 recipient of the prestigious “Golden Virus Award” an honor bestowed by the Organizing Committee of the International Oncolytic Virotherapy Conference in recognition of outstanding contributions to the field. Dr. Russell received the award in recognition of his longstanding leadership role in the field and his clinical demonstration of the feasibility of achieving complete remission of disseminated cancer after a single intravenous administration of an oncolytic virus, MV-NIS (Russell et al., Mayo Clinic Proceedings, 2014). Previous Golden Virus Awardees were Dr. Rob Coffin for the creation and development of talimogene laherparepvec (TVec), the first onolytic virus to gain regulatory marketing approval, both in Europe and the USA for the treatment of metastatic malignant melanoma, and Dr. Bob Martuza (Massachusetts General Hospital) for his pioneering work advancing a genetically engineered herpes simplex virus for the treatment of mouse glioma, and thereby establishing proof of principle for the use of engineered viruses as an anticancer therapy (Martuza et al., Science 1991)

No Comments

Sorry, the comment form is closed at this time.